Acute Gout Flare Market to Grow Positively at a Significant CAGR | Companies- Dyve Biosciences, R-Pharm, Swedish Orphan Biovitrum

(United States, Nevada, Las Vegas), DelveInsight's "Acute Gout Flare - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Acute Gout Flare market share of the individual therapies, current and forecasted Acute Gout Flare market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Gout Flare therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Gout Flare market.

Request for a Free Acute Gout Flare Market Sample Report @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Overview

Gout is a form of inflammatory arthritis that is triggered by the crystallization of monosodium urate (MSU) inside the joints and is preceded by hyperuricemia. Gout progresses in 4 stages: Asymptomatic hyperuriceamia, Acute gout flare/attack, intercritical period, and if left untreated the disease reaches the Chronic tophaceous gout. In general, Gout is a manageable disease if diagnosed and treated properly.

Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, and decreased physical function as the patients experience symptoms such as severe pain and inflammation in one or more joints. Epidemiology studies shoe that Gout has become more prevalent over the past few decades, affecting over 3% of adults in the US.
Risk factors include genetics, age, gender, and diet.
These factors may contribute to a high serum uric acid level, currently defined as a value of at least 6.8 mg per dL (405 μmol per L). Hyperuricemia is a primary risk factor for gout. Gout is more prevalent in males than females; It affects adults more than 60 years of age than younger population; Genetic pre-disposition for Gout, plays a vital role in disease progression. Excessive consumption of foods such as red meat, seafood, sugar-sweetened soft drinks, fructose and alcohol increase the risk of developing hyperuricemia.

According to American College of Rheumatology (ACR) guidelines, treatment of acute gout attacks involves pharmacological therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution.

Acute Gout Flare Diagnosis

Microscopy of joint fluid is used less often, primarily in equivocal cases. In these situations, the diagnosis is established by aspiration of a joint or tophus and identification of needle-shaped monosodium urate crystals, preferably intracellular, with bright, negative birefringence on compensated polarized light microscopy. Ultrasonography, magnetic resonance imaging, and computed tomography are typically not necessary for diagnosis.

The differential diagnosis for acute monoarticular joint swelling includes pseudogout, infection, and trauma. Pseudogout, or calcium pyrophosphate deposition disease, can mimic gout in clinical appearance and may respond to nonsteroidal anti-inflammatory drugs (NSAIDs). Findings of calcium pyrophosphate crystals and normal serum uric acid levels on joint fluid analysis can differentiate pseudogout from gout. Septic arthritis may present without a fever or elevated white blood cell count; arthrocentesis is required to distinguish this condition from acute gout. Gout and septic arthritis can occur concomitantly, but this is rare. Trauma-associated joint swelling is typically identified by the history; however, trauma may result in an acute gout flare caused by increased concentrations of synovial urate. Imaging may be necessary to rule out fracture in a patient with gout-like symptoms after a joint injury.

Acute Gout Flare Treatment

To achieve rapid and complete resolution of symptoms, treatment of acute gout should commence within 24 hours of symptom onset. Oral corticosteroids, intravenous corticosteroids, NSAIDs, and colchicine are equally effective in treating acute flares of gout. NSAIDs are the first-line treatment. Indomethacin (Indocin) has historically been the preferred choice; however, there is no evidence it is more effective than any other NSAID.

Learn more about Acute Gout Flare, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key highlights from the Acute Gout Flare Market Report:

As per NHANES, the prevalence of Gout in the US men was 5.2% (5.9 million) and 2.7% (3.3 million) among women, in 2015-2016. The disease prevalence increased with age, with the lowest gout prevalence (0.7% or 0.6 million) in individuals aged 20 to 39 years and the highest (8.7% or 1.0 million) in individuals aged 80 years or older.

The Acute Gout Flare epidemiology is segmented as Incident cases of Acute Gout Flare, Age-Specific cases of Acute Gout Flare, Gender-Specific cases of Acute Gout Flare in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Acute Gout Flare Epidemiological Insights

Gout is a common cause of inflammatory arthritis. Among the United States adult population, the gout prevalence is 3.9%.

Explore more about Acute Gout Flare Epidemiology at: https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Treatment Market

Current guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) advise that long-term urate-lowering therapy (ULT), with the aim of maintaining serum urate levels (generally below 6 mg/dL), is key to effective control of gout and should be initiated in the presence of certain clinical features: for example, tophi, frequent gouty attacks (flares; two or more per year), and urate arthropathy.

Effective options for the treatment of the acute attack include non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids and systemic corticosteroid therapy. With respect to efficacy (although not toxicity) the rapidity with which therapy is commenced appears to be more important than which medication is used. The best choice is often determined by whether or not there are contraindications to NSAID use, such as renal or cardiac insufficiency or a history of peptic ulceration.

Provided synovial fluid has been sent for analysis, including culture, it is reasonable to administer intra-articular corticosteroid immediately following joint aspiration (without removing the needle from the joint) when gout appears likely, even though sepsis has not yet been excluded. Systemic corticosteroid therapy can be provided as oral prednisone 20-40 mg daily in divided doses reducing to zero in 10-14 days or intramuscular depot tetracosactrin 1 mg, a synthetic analog of ACTH.

Request a sample and discover more about the Acute Gout Flare Market report offerings at: https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Promising Therapies in the Acute Gout Flare Pipeline
● DYV700
● RPH - 104
● Anakinra
● And others

Request for a sample report to understand more about the Acute Gout Flare pipeline development activities at: https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Acute Gout Flare Market
● Dyve Biosciences, Inc.
● R-Pharm
● Swedish Orphan Biovitrum
● And others

To understand key companies related to the Acute Gout Flare Market, get a snapshot of the Acute Gout Flare Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Acute Gout Flare Market Report
Study Period: 2019-2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Gout Flare Companies: Dyve Biosciences, Inc., R-Pharm, Swedish Orphan Biovitrum, and others.
Key Acute Gout Flare Pipeline Therapies: DYV700, RPH - 104, Anakinra, and others
Therapeutic Assessment: Acute Gout Flare current marketed and emerging therapies
Acute Gout Flare Market Dynamics: Acute Gout Flare market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement

Table of Contents

1. Acute Gout Flare Market Key Insights
2. Acute Gout Flare Market Report Introduction
3. Acute Gout Flare Market Overview at a Glance
4. Acute Gout Flare Market Executive Summary
5. Disease Background and Overview
6. Acute Gout Flare Treatment and Management
7. Acute Gout Flare Epidemiology and Patient Population
8. Patient Journey
9. Acute Gout Flare Emerging Drugs
10. 7MM Acute Gout Flare Market Analysis
11. Acute Gout Flare Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Gout Flare Market Drivers
15. Acute Gout Flare Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:

Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +1(919)321-6187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.